Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.

Hu X, Valentin A, Cai Y, Dayton F, Rosati M, Ramírez-Salazar EG, Kulkarni V, Broderick KE, Sardesai NY, Wyatt LS, Earl PL, Moss B, Mullins JI, Pavlakis GN, Felber BK.

Hum Gene Ther. 2018 Jun 21. doi: 10.1089/hum.2018.065. [Epub ahead of print]

PMID:
29869530
2.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group .

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

PMID:
29669026
3.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Viegas EO, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O, Stout R, Scarlatti G, Ferrari G, Earl PL, Wahren B, Andersson S, Robb ML, Osman N, Biberfeld G, Jani I, Sandström E.

AIDS Res Hum Retroviruses. 2017 Nov 27. doi: 10.1089/AID.2017.0121. [Epub ahead of print]

PMID:
28969431
4.

Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses.

Americo JL, Earl PL, Moss B.

Virology. 2017 Nov;511:19-22. doi: 10.1016/j.virol.2017.08.005. Epub 2017 Aug 10.

PMID:
28802157
5.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.12.1-5.12.18. doi: 10.1002/cpps.34.

PMID:
28762495
6.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18. doi: 10.1002/cpps.33.

7.

Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection.

Earl PL, Americo JL, Moss B.

J Virol. 2017 Sep 12;91(19). pii: e01042-17. doi: 10.1128/JVI.01042-17. Print 2017 Oct 1.

8.

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.

Wyatt LS, Xiao W, Americo JL, Earl PL, Moss B.

MBio. 2017 Jun 6;8(3). pii: e00790-17. doi: 10.1128/mBio.00790-17.

9.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Mol Biol. 2017 Jan 5;117:16.16.1-16.16.18. doi: 10.1002/cpmb.33.

PMID:
28060410
10.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Mol Biol. 2017 Jan 5;117:16.17.1-16.17.18. doi: 10.1002/cpmb.32.

PMID:
28060405
11.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, Tecleab T, Liakina V, Scarlatti G, Robb ML, Earl PL, Moss B, Wahren B, Mhalu F, Ferrari G, Sandstrom E, Biberfeld G.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):880-888. doi: 10.1089/AID.2016.0251. Epub 2017 Jan 27.

12.

A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model.

Reynolds SE, Earl PL, Minai M, Moore I, Moss B.

Virology. 2017 Jan 15;501:107-114. doi: 10.1016/j.virol.2016.11.010. Epub 2016 Nov 26.

13.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Microbiol. 2015 Nov 3;39:14A.4.1-18. doi: 10.1002/9780471729259.mc14a04s39.

14.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Microbiol. 2015 Nov 3;39:14A.3.1-18. doi: 10.1002/9780471729259.mc14a03s39.

15.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

16.

Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus.

Earl PL, Americo JL, Moss B.

Virology. 2015 Jul;481:161-5. doi: 10.1016/j.virol.2015.02.048. Epub 2015 Mar 17.

17.
18.

Elimination of A-type inclusion formation enhances cowpox virus replication in mice: implications for orthopoxvirus evolution.

Kastenmayer RJ, Maruri-Avidal L, Americo JL, Earl PL, Weisberg AS, Moss B.

Virology. 2014 Mar;452-453:59-66. doi: 10.1016/j.virol.2013.12.030. Epub 2014 Jan 29.

19.

Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging.

Americo JL, Sood CL, Cotter CA, Vogel JL, Kristie TM, Moss B, Earl PL.

Virology. 2014 Jan 20;449:120-32. doi: 10.1016/j.virol.2013.11.017. Epub 2013 Nov 28.

20.

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL.

Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24.

21.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

22.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

23.

Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response.

Earl PL, Americo JL, Moss B.

J Virol. 2012 Sep;86(17):9105-12. doi: 10.1128/JVI.00162-12. Epub 2012 Jun 13.

24.

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.

Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL.

Vaccine. 2012 Feb 21;30(9):1737-45. doi: 10.1016/j.vaccine.2011.12.026. Epub 2011 Dec 15.

25.

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, Moss B, Amara RR, Robinson HL.

J Infect Dis. 2011 Jul 1;204(1):164-73. doi: 10.1093/infdis/jir199.

26.

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Kannanganat S, Nigam P, Velu V, Earl PL, Lai L, Chennareddi L, Lawson B, Wilson RL, Montefiori DC, Kozlowski PA, Moss B, Robinson HL, Amara RR.

J Immunol. 2010 Dec 15;185(12):7262-73. doi: 10.4049/jimmunol.1000751. Epub 2010 Nov 12.

27.

Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models.

Americo JL, Moss B, Earl PL.

J Virol. 2010 Aug;84(16):8172-80. doi: 10.1128/JVI.00621-10. Epub 2010 Jun 2.

28.

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH.

Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3.

29.

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, Vogt J, Moss B.

J Virol. 2009 Jul;83(14):7176-84. doi: 10.1128/JVI.00687-09. Epub 2009 May 6.

30.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

31.

Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.

Fogg CN, Americo JL, Earl PL, Resch W, Aldaz-Carroll L, Eisenberg RJ, Cohen GH, Moss B.

J Virol. 2008 Aug;82(16):8022-9. doi: 10.1128/JVI.00568-08. Epub 2008 Jun 4.

32.

Characterization of recombinant vaccinia viruses and their products.

Earl PL, Moss B.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.14. doi: 10.1002/0471140864.ps0514s13.

PMID:
18429180
33.

Generation of recombinant vaccinia viruses.

Earl PL, Moss B, Wyatt LS, Carroll MW.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.13. doi: 10.1002/0471140864.ps0513s13.

PMID:
18429179
34.

Preparation of cell cultures and vaccinia virus stocks.

Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.12. doi: 10.1002/0471140864.ps0512s13.

35.

Overview of the vaccinia virus expression system.

Moss B, Earl PL.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.11. doi: 10.1002/0471140864.ps0511s13.

PMID:
18429177
36.

Overview of the vaccinia virus expression system.

Moss B, Earl PL.

Curr Protoc Mol Biol. 2002 Nov;Chapter 16:Unit16.15. doi: 10.1002/0471142727.mb1615s60.

PMID:
18265301
37.

Characterization of recombinant vaccinia viruses and their products.

Earl PL, Moss B.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.18. doi: 10.1002/0471142727.mb1618s43.

PMID:
18265125
38.

Generation of recombinant vaccinia viruses.

Earl PL, Moss B, Wyatt LS, Carroll MW.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.17. doi: 10.1002/0471142727.mb1617s43.

PMID:
18265124
39.

Preparation of cell cultures and vaccinia virus stocks.

Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.16. doi: 10.1002/0471142727.mb1616s43.

PMID:
18265123
40.

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, Liu J, Robinson HL, Moss B.

Vaccine. 2008 Jan 24;26(4):486-93. Epub 2007 Dec 3.

41.
42.

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.

Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B, Frey SE, Felgner PL.

J Virol. 2008 Jan;82(2):652-63. Epub 2007 Oct 31.

43.

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.

Nigam P, Earl PL, Americo JL, Sharma S, Wyatt LS, Edghill-Spano Y, Chennareddi LS, Silvera P, Moss B, Robinson HL, Amara RR.

Virology. 2007 Sep 15;366(1):73-83. Epub 2007 May 16.

44.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B.

Virology. 2007 Sep 15;366(1):84-97. Epub 2007 May 11.

45.

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.

Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, Resch W, Earl PL, Klinman DM, Moss B.

Vaccine. 2007 Apr 12;25(15):2787-99. Epub 2007 Jan 3.

46.

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.

Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR.

Virology. 2006 Sep 1;352(2):285-94. Epub 2006 Jun 5.

47.
48.

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.

Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):654-65.

PMID:
15242543
49.

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.

Wyatt LS, Earl PL, Liu JY, Smith JM, Montefiori DC, Robinson HL, Moss B.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):645-53.

PMID:
15242542
50.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.

Supplemental Content

Support Center